Payment overview · 2025
General Payments
$415.00
21 reported records · 8 companies
Healthcare provider profile · identity verified
Ginger N Pace-Herndon, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SUMRALL, MS · NPI 1649480971
Verified facts
What the public records show
CMS Open Payments records show Ginger N Pace-Herndon, M.D. received $415.00 in general payments during 2025 across 21 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $106.86 | 25.8% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $106.20 | 25.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $94.80 | 22.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.21 | 7.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.93 | 5.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.68 | 5.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.59 | 4.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.73 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $415.00 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $106.86 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $106.20 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $76.09 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 50 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
75 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
65 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
50 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 555 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 553 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 465 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 392 | 78 |
| Losartan Potassium | Losartan Potassium | 341 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 285 | 54 |
| Omeprazole | Omeprazole | 274 | 51 |
| Lisinopril | Lisinopril | 260 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 44 |
| Furosemide | Furosemide | 230 | 54 |
| Metformin Hcl | Metformin Hcl | 220 | 42 |
| Trazodone Hcl | Trazodone Hcl | 216 | 41 |
| Celecoxib | Celecoxib | 188 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 169 | 32 |
| Carvedilol | Carvedilol | 167 | 37 |
| Prednisone | Prednisone | 167 | 92 |
| Diclofenac Sodium | Diclofenac Sodium | 165 | 44 |
| Alprazolam | Alprazolam | 148 | 15 |
| Potassium Chloride | Potassium Chloride | 147 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 29 |
| Meloxicam | Meloxicam | 141 | 29 |
| Tramadol Hcl | Tramadol Hcl | 139 | 29 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 128 | 82 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 124 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 117 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 111 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 107 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 106 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 23 |
| Montelukast Sodium | Montelukast Sodium | 101 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 27 |
| Mounjaro | Tirzepatide | 95 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 33 |
| Simvastatin | Simvastatin | 94 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 20 |
| Metformin Hcl Er | Metformin Hcl | 83 | 17 |
| Ibuprofen | Ibuprofen | 82 | 12 |
| Januvia | Sitagliptin Phosphate | 82 | 15 |
| Eliquis | Apixaban | 80 | 14 |
| Sertraline Hcl | Sertraline Hcl | 79 | 18 |
| Fluconazole | Fluconazole | 77 | 39 |
| Allopurinol | Allopurinol | 76 | 15 |
| Linzess | Linaclotide | 75 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 21 |
| Clonazepam | Clonazepam | 71 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 12 |
| Glipizide Er | Glipizide | 65 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 65 | 20 |
| Aripiprazole | Aripiprazole | 64 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 63 | 15 |
| Estradiol | Estradiol | 62 | 13 |
| Azithromycin | Azithromycin | 60 | 44 |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 15 |
| Glimepiride | Glimepiride | 57 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 55 | 15 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 53 | 51 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 14 |
| Buspirone Hcl | Buspirone Hcl | 50 | 17 |
| Doxepin Hcl | Doxepin Hcl | 50 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 50 | 35 |
| Spironolactone | Spironolactone | 50 | 12 |
| Farxiga | Dapagliflozin Propanediol | 48 | suppressed |
| Diazepam | Diazepam | 47 | suppressed |
| Amoxicillin | Amoxicillin | 45 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 13 |
| Ozempic | Semaglutide | 45 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 44 | suppressed |
| Famotidine | Famotidine | 43 | suppressed |
| Glipizide | Glipizide | 43 | 11 |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 24 |
| Jardiance | Empagliflozin | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 21 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | 11 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $415.00 · 21 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | AIRSUPRA, AREXVY, FARXIGA, JARDIANCE, Kerendia, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, VRAYLAR, WaveWriter Alpha Prime 16, XIFAXAN | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error